Stop treating India as backup: Biopharma leaders bet big on clinical trials

Executives from Bayer, Parexel, Takeda, Unilabs, and Nestlé Health Science agreed that global companies must now approach India with deliberate focus and long-term commitment.

leaders at the USAIC 19th Annual Biopharma & Healthcare Summit / New India Abroad

Biopharma leaders at the USAIC 19th Annual Biopharma & Healthcare Summit pushed for India as a core destination in global drug development, stating that the country is rapidly shedding its image as a backup market for clinical trials.

“Let’s stop treating India as a backup. It’s time to make it part of the core strategy” said Badhri Srinivasan, executive chairman of Unilabs at the event hosted by USA-India Chamber of Commerce.

Also Read: Experts discuss AI-driven healthcare advances at TiECon 2025

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login